For example, many breast cancer patients received both estrogen receptor (ER) antagonist and aromatase inhibitor therapy, and many patients received more than one genotoxic therapy (e.g., anthracyclines, DNA alkylating agent, DNA synthesis inhibitor). This evidence concerns the gene ESR1 and breast carcinoma.